CD274 and cancer: In particular, we would like to propose that combination therapies with Pxl, and possibly its derivatives, and ICIs, especially anti PD-L1/PD targets, should be approached first by a low dosage, rather than near to maximum tolerated, Pxl regimen in order to render “hot” the tumor microenvironment and to “prime” cancer cells for a sequential, rather than concurrent, treatment with ICIs (see Figure 5) (14, 15, 27, 35, 39).